Abstract
Women with preexisting cardiomyopathy, such as dilated cardiomyopathy, who are followed closely during pregnancy often tolerate pregnancy and delivery. Many symptoms of a normal pregnancy can mimic heart failure in the antepartum period, and repeated maternal echocardiographic imaging is necessary during pregnancy. Risk factors for adverse outcomes include functional status at baseline and severity of systolic dysfunction. Beta-blockers are generally safe during pregnancy, but some reports suggest that they can cause intrauterine growth restriction. Cardiac complications such as worsening heart failure accompanied by worsening left ventricular ejection fraction (LVEF), arrhythmias, and cerebrovascular accidents occur most commonly in late pregnancy, as well as in the first 16 months postpartum. The level of brain natriuretic peptide (BNP) can be used to risk stratify women for adverse events. Pregnant women with dilated cardiomyopathy should be followed closely by a multidisciplinary team comprised of nurses, obstetricians, neonatologists, cardiologists, anesthesiologists, and cardiac surgeons. The team should ideally discuss a delivery plan prior to commencement of labor, with identification of the type of labor, anesthesia, and need for invasive hemodynamic monitoring.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bernstein PS, Magriples U (2001) Cardiomyopathy in pregnancy: a retrospective study. Am J Perinatol 18:163–168
Burkett EL, Hershberger RE (2005) Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 45:969–981
Sivasankaran S, Sharland GK, Simpson JM (2005) Dilated cardiomyopathy presenting during fetal life. Cardiol Young 15:409–416
Judge DP (2009) Use of genetics in the clinical evaluation of cardiomyopathy. JAMA 302:2471–2476
Dellefave L, McNally EM (2010) The genetics of dilated cardiomyopathy. Curr Opin Cardiol 25:198–204
Hershberger RE, Morales A, Siegfried JD (2010) Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 12:655–667
Hershberger RE, Siegfried JD (2011) State of the art review. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 57:1641–1649
Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239
Roos-Hesselink J, Ruys T, Stein J, Thilén U, Webb G, Niwa K et al (2013) Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J 34:657–665
Vanita S, Neelam A, Arun K, Seema C, Pooja S, Rajesh V (2013) Pregnancy with dilated and peripartum cardiomyopathy: maternal and fetal outcome. Arch Gynecol Obstet 287:195–199
Katsuragi S, Omoto A, Kamiya C, Ueda K, Sasaki Y, Yamanaka K et al (2012) Risk factors for maternal outcome in pregnancy complicated with dilated cardiomyopathy. J Perinatol 32:170–175
Grewal J, Siu S, Ross H, Mason J, Balint O, Sermer M et al (2010) Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 55:45–52
European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L, ESC Committee for Practice Guidelines (2011) ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of pregnancy of the European Society of Cardiology (ESC). Eur Heart J 32:3147–3197
Thorne S, MacGregor A, Nelson-Piercy C (2006) Risks for contraception and pregnancy in heart disease. Heart 92:1520–1525
Gevaert S, Paum M, Tromp F, Ascoop A, Roelens K et al (2014) Treatment of pre-existing cardiomyopathy during pregnancy. Acta Cardiol 69:193–196
Cooper WO, Heenandez-Diaz S, Arbogast PG, Dudly JA, Dyer S, Gideon PS et al (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443–2451
Messina M, Biffignandi P, Ghigo E, Jeanter MG, Molinatti GM (1979) Possible contraindication of spironolactone during pregnancy. J Endocrinol Investig 2:222
Widerhorn J, Rubin JN, Frishman WH, Elkayam U (1987) Cardiovascular drugs in pregnancy. Cardiol Clin 5:651–674
Tanaka K, Tanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M et al (2016) Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J 80:2221–2226
Meidahl PK, Jimenez SE, Andersen JT, Petersen M, Brodbaek K, Kober L et al (2012) β-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open 2:e001185
Kathleen S, Elaine S, Travis B (2011) Pregnancy in patients with pre-existing cardiomyopathies. J Am Coll Cardiol 58:337–350
Hameed AB, Chan K, Ghamsary M, Elkayam U (2009) Longitudinal changes in the B-type natriuretic peptide levels in normal pregnancy and postpartum. Clin Cardiol 32:E60–E62
Resnik JL, Hong C, Resnik R et al (2005) Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 193:450–454
Folk JJ, Lipari CW, Nosovitch JT, Silverman RK, Carlson RJ, Navone AJ (2005) Evaluating ventricular function with B-type natriuretic peptide in obstetric patients. J Reprod Med 50:147–154
Borghi C, Esposti DD, Immordino V et al (2000) Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia. Am J Obstet Gynecol 183:140–147
Rafik Hamad R, Larsson A, Pernow J, Bremme K, Eriksson MJ (2009) Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens 27:2257–2264
Tanous D, Siu SC, Mason J et al (2010) B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 56:1247–1253
Howlett JG, McKelvie RS, Costigan J et al (2010) The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol 26:185–202
Secher NJ, Thayssen P, Arnsbo P, Olsen J (1982) Effect of prostaglandin E2 and F2alpha on the systemic and pulmonary circulation in pregnant anesthetized women. Acta Obstet Gynecol Scand 61:213–218
Siu SC, Sermer M, Harrison DA et al (1997) Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 96:2789–2794
Geva T, Mauer MB, Striker L, Kirshon B, Pivarnik JM (1997) Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. Am Heart J 133:53–59
Pryn A, Bryden F, Reeve W, Young S, Patrick A, McGrady EM (2007) Cardiomyopathy in pregnancy and caesarean section: four case reports. Int J Obstet Anesth 16:68–73
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Katsuragi, S., Ikeda, T. (2019). Dilated Cardiomyopathy. In: Ikeda, T., Aoki-Kamiya, C. (eds) Maternal and Fetal Cardiovascular Disease. Springer, Singapore. https://doi.org/10.1007/978-981-10-1993-7_9
Download citation
DOI: https://doi.org/10.1007/978-981-10-1993-7_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-1991-3
Online ISBN: 978-981-10-1993-7
eBook Packages: MedicineMedicine (R0)